Literature DB >> 30218825

Determination of intestinal permeability using in situ perfusion model in rats: Challenges and advantages to BCS classification applied to digoxin.

Tamires Guedes Caldeira1, Alejandro Ruiz-Picazo2, Isabel Lozoya-Agullo2, Dênia Antunes Saúde-Guimarães3, Marta González-Álvarez2, Jacqueline de Souza4, Isabel González-Álvarez5, Marival Bermejo2.   

Abstract

The purpose of this work was to describe the closed loop in situ perfusion method in rats and to compare the difficulties and advantages with other methods proposed by regulatory agencies for BCS classification and finally to illustrate its application to evaluate the permeability of digoxin at relevant clinical concentrations. Digoxin was evaluated at two concentration levels: 1.0 μg/ml (with and without sodium azide 65.0 μg/ml) and 6.0 μg/ml. These concentrations correspond to the ratio of the highest dose strength (0.25 mg) and the highest single dose administered (1.5 mg) and the 250 ml of water. In situ closed loop perfusion studies in rats were performed in the whole small intestine and also in duodenum, jejunum and ileum segments to evaluate the relevance of P-gp secretion in the overall permeability. A kinetic modelling approach involving passive permeation and efflux transport mechanism allowed the estimation of the passive diffusional component and the Michaelis-menten parameters. The estimated Km value demonstrated that at clinical luminal concentrations the efflux process is not saturated and then it could be inhibited by other drugs, excipients or food components leading to the already reported clinical drug-drug and drug-food interations. The present data confirms from a mechanistic point of view these interactions.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biopharmaceutic Classification System; Digoxin; In situ perfusion; Intestinal absorption; Permeability

Mesh:

Substances:

Year:  2018        PMID: 30218825     DOI: 10.1016/j.ijpharm.2018.09.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination.

Authors:  Tamires Guedes Caldeira; Dênia Antunes Saúde-Guimarães; Isabel González-Álvarez; Marival Bermejo; Jacqueline de Souza
Journal:  Daru       Date:  2021-04-22       Impact factor: 3.117

2.  Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats.

Authors:  Anallely López-Yerena; Anna Vallverdú-Queralt; Raf Mols; Patrick Augustijns; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2020-02-05       Impact factor: 6.321

3.  Integrated Strategy From In Vitro, In Situ, In Vivo to In Silico for Predicting Active Constituents and Exploring Molecular Mechanisms of Tongfengding Capsule for Treating Gout by Inhibiting Inflammatory Responses.

Authors:  Wenning Yang; Xiaoquan Jiang; Jingtong Liu; Dongying Qi; Zhiqiang Luo; Guohua Yu; Xueyan Li; Muli Sen; Hongjiao Chen; Wei Liu; Yang Liu; Guopeng Wang
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

Review 4.  Evaluation of Excipient Risk in BCS Class I and III Biowaivers.

Authors:  Melissa Metry; James E Polli
Journal:  AAPS J       Date:  2022-01-05       Impact factor: 4.009

Review 5.  Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence.

Authors:  Samar Zuhair Alshawwa; Abeer Ahmed Kassem; Ragwa Mohamed Farid; Shaimaa Khamis Mostafa; Gihan Salah Labib
Journal:  Pharmaceutics       Date:  2022-04-18       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.